JP2022515194A5 - - Google Patents
Info
- Publication number
- JP2022515194A5 JP2022515194A5 JP2021536031A JP2021536031A JP2022515194A5 JP 2022515194 A5 JP2022515194 A5 JP 2022515194A5 JP 2021536031 A JP2021536031 A JP 2021536031A JP 2021536031 A JP2021536031 A JP 2021536031A JP 2022515194 A5 JP2022515194 A5 JP 2022515194A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- pharmaceutical composition
- composition according
- mage
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024046429A JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782131P | 2018-12-19 | 2018-12-19 | |
| US62/782,131 | 2018-12-19 | ||
| PCT/US2019/067613 WO2020132327A1 (en) | 2018-12-19 | 2019-12-19 | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046429A Division JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515194A JP2022515194A (ja) | 2022-02-17 |
| JP2022515194A5 true JP2022515194A5 (https=) | 2022-12-26 |
| JP7620374B2 JP7620374B2 (ja) | 2025-01-23 |
Family
ID=71102914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536031A Active JP7620374B2 (ja) | 2018-12-19 | 2019-12-19 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
| JP2024046429A Active JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046429A Active JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11673964B2 (https=) |
| EP (1) | EP3898692A4 (https=) |
| JP (2) | JP7620374B2 (https=) |
| KR (1) | KR20220002859A (https=) |
| CN (2) | CN113454117B (https=) |
| AU (1) | AU2019404302A1 (https=) |
| CA (1) | CA3124467A1 (https=) |
| IL (1) | IL284196A (https=) |
| MX (1) | MX2021007547A (https=) |
| SG (1) | SG11202106699VA (https=) |
| WO (1) | WO2020132327A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013126729A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| WO2022061115A1 (en) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| CA3196831A1 (en) * | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022089644A1 (zh) * | 2020-11-01 | 2022-05-05 | 南京驯鹿医疗技术有限公司 | 靶向cd5的全人源抗体、全人源嵌合抗原受体(car)及其应用 |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4279508A4 (en) * | 2021-01-12 | 2024-12-04 | Nanjing Iaso Biotechnology Co., Ltd. | Cd5-targeting fully humanized antibody |
| KR20230171919A (ko) * | 2021-02-11 | 2023-12-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ccr4 표적화 키메라 항원 수용체 세포 요법 |
| CN115044617B (zh) * | 2021-03-08 | 2024-08-13 | 河北森朗生物科技有限公司 | Car t细胞的制备方法、car t细胞及其应用 |
| WO2022197949A2 (en) | 2021-03-17 | 2022-09-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| BR112023023642A2 (pt) | 2021-05-11 | 2024-01-30 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
| CN115989244A (zh) * | 2021-08-06 | 2023-04-18 | 上海驯鹿生物技术有限公司 | Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用 |
| WO2023114777A2 (en) * | 2021-12-14 | 2023-06-22 | The Trustees Of The University Of Pennsylvania | Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors |
| CN114645022B (zh) * | 2022-05-13 | 2022-09-02 | 首都医科大学宣武医院 | 靶向CD5的CAR-γ δ T细胞及其制备方法与应用 |
| CN117431217A (zh) * | 2022-07-12 | 2024-01-23 | 上海驯鹿生物技术有限公司 | 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用 |
| KR102869461B1 (ko) * | 2022-10-05 | 2025-10-17 | 주식회사 지씨셀 | Cd5를 표적하는 키메라 항원 수용체 및 이를 발현하는 면역세포 |
| EP4716744A2 (en) * | 2023-05-23 | 2026-04-01 | Vittoria Biotherapeutics, Inc. | Genetically modified cells comprising a heterologous nucleic acid molecule inserted at a cd5 gene locus field |
| CN121969384A (zh) * | 2023-05-31 | 2026-05-01 | 维多利亚生物治疗公司 | 制造t细胞的方法 |
| CN119529071B (zh) * | 2023-08-28 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗登革病毒或其ns1蛋白的抗体及其应用 |
| WO2025122896A1 (en) * | 2023-12-08 | 2025-06-12 | The Trustees Of The University Of Pennsylvania | Cd5 modified cells comprising heterologous tcrs and methods of using the same |
| CN118891290A (zh) * | 2024-04-12 | 2024-11-01 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951983A (en) | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
| RU2011111640A (ru) | 2008-08-29 | 2012-10-10 | Симфоген А/С (Dk) | Антитела против cd5 |
| JP2017512304A (ja) * | 2014-02-06 | 2017-05-18 | イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ | バイオマーカーシグネチャー法ならびにそのための装置およびキット |
| JP7237449B2 (ja) | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| AU2018246377B2 (en) * | 2017-03-31 | 2025-01-30 | Cellectis Sa | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
| CA3065126A1 (en) | 2017-06-01 | 2018-12-06 | Innovative Cellular Therapeutics CO., LTD. | Chimeric antigen receptor cell preparation and uses thereof |
-
2019
- 2019-12-19 CN CN201980092281.9A patent/CN113454117B/zh active Active
- 2019-12-19 EP EP19898610.1A patent/EP3898692A4/en active Pending
- 2019-12-19 CN CN202510805788.1A patent/CN121059792A/zh active Pending
- 2019-12-19 WO PCT/US2019/067613 patent/WO2020132327A1/en not_active Ceased
- 2019-12-19 JP JP2021536031A patent/JP7620374B2/ja active Active
- 2019-12-19 AU AU2019404302A patent/AU2019404302A1/en active Pending
- 2019-12-19 US US17/416,365 patent/US11673964B2/en active Active
- 2019-12-19 CA CA3124467A patent/CA3124467A1/en active Pending
- 2019-12-19 KR KR1020217022614A patent/KR20220002859A/ko active Pending
- 2019-12-19 SG SG11202106699VA patent/SG11202106699VA/en unknown
- 2019-12-19 MX MX2021007547A patent/MX2021007547A/es unknown
-
2021
- 2021-06-20 IL IL284196A patent/IL284196A/en unknown
-
2023
- 2023-04-21 US US18/304,843 patent/US20230331864A1/en active Pending
-
2024
- 2024-03-22 JP JP2024046429A patent/JP7843056B2/ja active Active
- 2024-03-28 US US18/620,748 patent/US12227588B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515194A5 (https=) | ||
| JP2018518978A5 (https=) | ||
| JP2020508663A5 (https=) | ||
| JP2020504628A5 (https=) | ||
| US12590148B2 (en) | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy | |
| JP2021035366A5 (https=) | ||
| ES2973524T3 (es) | Métodos para mejorar la eficacia de la transducción de vectores en los linfocitos T | |
| ES2898270T3 (es) | Linfocitos T modificados con especificidad mejorada | |
| AU2014240083B2 (en) | Modified T lymphocytes | |
| JP2026053384A (ja) | チェックポイント分子を標的とするｄｎａモノクロナール抗体 | |
| JP2020504628A (ja) | 多官能性タンパク質 | |
| JP2010533649A5 (https=) | ||
| HRP20221167T1 (hr) | Čestice arenavirusa kao cjepiva protiv raka | |
| JP2025106247A (ja) | エンジニアリングされた免疫細胞 | |
| CN110392736A (zh) | 遗传修饰的反抑细胞及其在免疫治疗中的用途 | |
| US12195536B2 (en) | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer | |
| US20250250348A1 (en) | Bispecific Binding Molecules That Target FSHR and CD3 | |
| US20250257131A1 (en) | Bispecific T Cell Engagers Targeting Tumor Antigens | |
| CN106478823B (zh) | Her1靶向性的嵌合抗原受体和nkt细胞及其制法和应用 | |
| HK40129547A (zh) | 靶向检查点分子的dna单克隆抗体 | |
| HK40129546A (zh) | 靶向检查点分子的dna单克隆抗体 | |
| HK40129545A (zh) | 靶向检查点分子的dna单克隆抗体 | |
| HK40129533A (zh) | 靶向检查点分子的dna单克隆抗体 | |
| WO2025072081A1 (en) | Enriched t-cell populations | |
| WO2024228167A1 (en) | Inkt cell modulator liposomal compositions and methods of use |